



US006673843B2

(12) **United States Patent**
Arbiser

(10) **Patent No.:** **US 6,673,843 B2**
(45) **Date of Patent:** ***Jan. 6, 2004**

(54) **CURCUMIN AND CURCUMINOID
INHIBITION OF ANGIOGENESIS**

(75) Inventor: **Jack L. Arbiser**, Atlanta, GA (US)
(73) Assignee: **Emory University**, Atlanta, GA (US)

(*) Notice: This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/345,712**

(22) Filed: **Jun. 30, 1999**

(65) **Prior Publication Data**

US 2002/0006966 A1 Jan. 17, 2002

(51) **Int. Cl.**⁷ **A61K 31/12**; A61K 13/00

(52) **U.S. Cl.** **514/679**; 424/422

(58) **Field of Search** 514/679; 424/422

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,704,383	A	11/1987	McNamara et al.	
4,900,815	A	2/1990	Tanaka et al.	
4,925,833	A	5/1990	McNamara et al.	
4,935,411	A	6/1990	McNamara et al.	
4,975,422	A	12/1990	Kanoh et al.	
5,290,807	A	3/1994	Folkman et al.	
5,401,504	A	3/1995	Das et al.	
5,576,330	A	11/1996	Buzzetti et al.	
5,629,340	A	5/1997	Kuwano et al.	
5,639,725	A	6/1997	O'Reilly	
5,654,312	A *	8/1997	Andrulis, Jr. et al.	514/279
5,670,493	A	9/1997	Cordi et al.	
5,712,291	A	1/1998	D'Amato	
5,733,876	A	3/1998	O'Reilly et al.	
5,861,415	A *	1/1999	Majeed et al.	514/321
5,891,924	A	4/1999	Aggarwal	
5,925,376	A *	7/1999	Heng	424/451

FOREIGN PATENT DOCUMENTS

JP	06128133	A *	5/1994
JP	10120558	A *	10/1996
JP	10120558	A *	5/1998
JP	11-92363	*	4/1999
JP	11092363	*	4/1999
WO	9518606	*	7/1995

OTHER PUBLICATIONS

Dipiro et al. *Pharmacotherapy A Pathophysiologic Approach*. 1989. pp. 960-961.*
Arbiser et al. "Curcumin is an in vivo inhibitor of angiogenesis"; *Molecular Medicine*, vol. 4, No. 6, pp. 376-383; ISSN: 1076-1551, Jun. 1998.*
Arbiser, et al., "Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways," *Proc Natl Acad Sci U S A*. 94(3):861-6 (1997).

Bille, et al., "Subchronic oral toxicity of turmeric oleoresin in pigs," *Food Chem Toxicol*. 23(11):967-73 (1985).

Conney, et al., "Inhibitory effect of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin," *Adv. Enzyme Regul.* 31:385-96 (1991).

Elayan, et al., "Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine but not by 2-hydroxy-4,5-methylenedioxymethamphetamine or 2-hydroxy-4,5-methylenedioxymphetamine," *Eur. J. Pharmacol.* 221 (2-3):281-8 (1992).

Folkman, "Antiangiogenic gene therapy," *Proc. Natl. Acad. Sci. U. S. A.* 95(16):9064-6 (1998).

Folkman, "Diagnostic and therapeutic applications of angiogenesis research," *C. R. Acad. Sci. III.* 316(9):914-18 (1993).

Folkman, et al., "Long-term culture of capillary endothelial cells," *Proc. Natl. Acad. Sci. U. S. A.* 76(10):5217-21 (1979).

Genetic Engineering News, 18(17):1, 8, 34, 46 (1998).

Golub, et al., "A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity," *J. Dent. Res.* 1987 Aug;66(8):1310-4.

Golub, et al., "Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources," *J. Periodontal Res.* 20(1):12-23 (1985).

Golub, et al., "Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action," *J. Periodontal Res.* 18(5):516-26 (1983).

(List continued on next page.)

Primary Examiner—Theodore J. Criares
Assistant Examiner—Jennifer Kim
(74) *Attorney, Agent, or Firm*—Holland & Knight LLP

(57) **ABSTRACT**

Methods for treating diseases or disorders of the skin which are characterized by angiogenesis have been developed using curcumin and curcumin analogs. Based on the results obtained with curcumin, it has been determined that other angiogenesis inhibitors can also be used to treat these skin disorders. It has further been discovered that curcumin acts to inhibit angiogenesis in part by inhibition of basic fibroblast growth factor (bFGF), and thereby provides a means for treating other disorders characterized by elevated levels of bFGF, such as bladder cancer, using curcumin and other analogues which also inhibit bFGF. Representative skin disorders to be treated include the malignant diseases angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Kaposi's sarcoma, and the non-malignant diseases or conditions including psoriasis, lymphangiogenesis, heman-gioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis.

7 Claims, 3 Drawing Sheets